Full Title
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid TumorsPurpose
The purpose of this study is to find the best dose of HST-1011 for people with advanced solid tumors. The people in this study have cancer that spread (metastasized) and keeps growing even after getting treatment.
HST-1011 may boost your immune system to help your body fight cancer. It does this by attaching to a specific protein. HST-1011 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic solid tumor that keeps growing after treatment.
- Have finished prior chemotherapy at least 3 weeks before getting HST-1011 (2 weeks since radiation therapy).
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Claire Friedman’s office at 646-888-4247.
Protocol
23-123
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT05662397